RRML - Alpha-methylacyl-CoA-racemase expression in variants and unusual patterns of prostate carcinoma
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17


Advanced search


Top 10 downloaded articles
- December 2022 -
 
Downregulation of hsa-miR-4328... 5
Normality assessment, few para... 4
High DNAJA4 expression correla... 4
Setting up an own laboratory p... 4
New Para-Clinical Investigatio... 3
Genetic risk factors for throm... 3
miR-190, CDK1, MCM10 and NDC80... 3
The relationship between matri... 2
A model for calculating measur... 2
The Use of Infrared Spectrosco... 2

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 19(4)/2011
XML
TXT

Alpha-methylacyl-CoA-racemase expression in variants and unusual patterns of prostate carcinoma

Alis Dema, Sorina M Taban, Elena Lazar, Denisa Anderco, Andrada Loghin, Codruta Lazureanu, Diana Herman, Angela Borda


Abstract:

Introduction: Alpha-methylacyl-CoA-racemase (AMACR) is a tumor marker expressed in prostate cancer. Literature data concerning its expression in different variants and unusual patterns of prostate carcinoma are uneven and less numerous. The present study investigates the AMACR expression in some rare forms of prostate carcinoma. Material and methods: Distinct variants and unusual patterns of prostate carcinoma (in pure or mixed form) were selected: foamy gland (9 cases), ductal adenocarcinoma (7 cases), pseudohyperplastic (5 cases), atrophic (3 cases), urothelial (3 cases), mucinous (2 cases), signet ring cell carcinoma (1 case) together with 20 cases of conventional prostate carcinomas. IHC study was performed using the following antibodies: AMACR, high molecular weight cytokeratin HMWCK, p63, PSA, prostein, CK5/6, CK7 and CK20. Results: Ninety percent of conventional prostate carcinomas cases were positive for AMACR. 5 out of the 30 variants/unusual patterns of prostate carcinoma cases were devoid of immunoreactivity for AMACR, including 2 ductal adenocarcinomas, 2 urothelial and an atrophic carcinoma. Carcinomas/areas of foamy, pseudohyperplastic and mucinous type have shown a marked heterogeneous expression of AMACR, with negative areas and foci of variable intense positive staining. Conclusions: This study confirms the heterogeneity of AMACR expression in prostate carcinomas and the fact that this marker's expression is reduced/absent in some cases of conventional or variants/unusual patterns of prostate carcinomas. In difficult cases or small biopsy specimens, the diagnosis of cancer should be based on correlation of data offered by the usual stains with findings provided by immunostaining for basal cells and AMACR.

Keywords: AMACR,immunohistochemistry,prostate,variants/unusual patterns of carcinoma

 
  PDF Download full text PDF
(619 KB)
     
 
How to cite
Dema A, Taban SM, Lazar E, Anderco D, Loghin A, Lazureanu C, et al. Alpha-methylacyl-CoA-racemase expression in variants and unusual patterns of prostate carcinoma. Rev Romana Med Lab. 2011;19(4):319-31